Andrew Green, MD
Gynecologic Oncology · Shreveport, LANPI 1396943973
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,600 of the $53,348 with a category attached, or 78.0%. 28 manufacturers reported payments, led by Tesaro, Inc. at 43.9% of the total. Reporting peaked in 2019 at $24,195 and has fallen 95.4% since, to $1,117 in 2025.
Across 241 payments — averaging $221.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$23K
- GSK$21K
- Intuitive Surgical$6K
- Hologic Sales And Service, LLC$624
- Myriad Genetic Laboratories, Inc.$606
- AstraZeneca$291
- plus $2K from 22 others
Across 100 payments — averaging $7652.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$370K
- Merck$314K
- Novocure Inc.$80K
- F. Hoffmann-la Roche AG$461
What the payments were for
- Speaking & faculty fees$41,60078%
- Travel & lodging$3,9827%
- Food & beverage$7,69714%
- Education$140%
- Gifts$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 57 | $23,405 |
| GSK | 37 | $21,142 |
| Intuitive Surgical | 45 | $5,753 |
| Hologic Sales And Service, LLC | 9 | $624 |
| Myriad Genetic Laboratories, Inc. | 10 | $606 |
| AstraZeneca | 15 | $291 |
| Merck | 17 | $283 |
| Medtronic | 3 | $245 |
| Clovis Oncology, Inc. | 9 | $154 |
| Eisai Inc. | 7 | $145 |
| Daiichi Sankyo Inc. | 7 | $123 |
| Aroa Biosurgery Incorporated | 2 | $114 |
| Seagen Inc. | 3 | $75 |
| Pfizer | 2 | $46 |
| Genentech USA, Inc. | 3 | $46 |
| KCI USA, Inc. | 2 | $40 |
| Heron Therapeutics, Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $29 |
| Novartis | 1 | $24 |
| Immunogen, Inc. | 1 | $22 |
| AbbVie | 1 | $22 |
| Olympus America Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Biom'up France SAS | 1 | $20 |
| Fortovia Therapeutics, Inc. | 1 | $20 |
| Morphosys, US Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $18 |
| Davol Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$42,698
- DA VINCI SP$3,000
- Da Vinci Surgical System$1,040
- NovaSure$370
- ACESSA PROVU SYSTEM$252
- myRisk$226
- ProGrip$199
- myChoice CDx$138
- MYOSURE TISSUE REMOVAL DEVICE$118
How this compares
Too few gynecologic oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 12 | $249 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Shreveport
- Destin BlackShreveport$61K
- Ricky OwersShreveport$19
- Patricia BralyCovington$130K
- Jacob EstesNew Orleans$16K
- Katrina WadeNew Orleans$8K
- Jessica ShankNew Orleans$4K
- David BarringtonNew Orleans$2K
- Diogo TorresNew Orleans$2K
- Amma AgyemangMetairie$2K
- Pui ChengNew Orleans$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.